185 related articles for article (PubMed ID: 34956885)
1. Response Evaluation and Survival Prediction Following PD-1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria.
Zhou M; Zhang C; Nie J; Sun Y; Xu Y; Wu F; Huang Y; Li S; Wang Y; Zhou Y; Zheng T
Front Oncol; 2021; 11():764189. PubMed ID: 34956885
[TBL] [Abstract][Full Text] [Related]
2. Comparative assessment of standard and immune response criteria for evaluation of response to PD-1 monotherapy in unresectable HCC.
Lewis S; Cedillo MA; Lee KM; Bane O; Hectors S; Ma W; Wang P; Stocker D; Morris DV; Pinato D; Sung M; Marron T; Schwartz M; Taouli B
Abdom Radiol (NY); 2022 Mar; 47(3):969-980. PubMed ID: 34964909
[TBL] [Abstract][Full Text] [Related]
3. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
Edeline J; Boucher E; Rolland Y; Vauléon E; Pracht M; Perrin C; Le Roux C; Raoul JL
Cancer; 2012 Jan; 118(1):147-56. PubMed ID: 21713764
[TBL] [Abstract][Full Text] [Related]
4. Response Evaluation and Survival Prediction After PD-1 Immunotherapy in Patients with Non-Small Cell Lung Cancer: Comparison of Assessment Methods.
Ayati N; Lee ST; Zakavi SR; Cheng M; Lau WFE; Parakh S; Pathmaraj K; Scott AM
J Nucl Med; 2021 Jul; 62(7):926-933. PubMed ID: 33246978
[TBL] [Abstract][Full Text] [Related]
5. Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma.
Ogasawara S; Kanai F; Ooka Y; Motoyama T; Suzuki E; Tawada A; Chiba T; Yokosuka O
Hepatol Int; 2013 Jun; 7(2):703-13. PubMed ID: 26201804
[TBL] [Abstract][Full Text] [Related]
6. Comparison of RECIST and iRECIST criteria in patients with advanced lung cancer treated with nivolumab.
Singla R; Jajodia A; Agrawal RK; Rao A; Pasricha S; Batra U
J Cancer Res Ther; 2023; 19(5):1212-1218. PubMed ID: 37787285
[TBL] [Abstract][Full Text] [Related]
7. Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.
Takada J; Hidaka H; Nakazawa T; Kondo M; Numata K; Tanaka K; Matsunaga K; Okuse C; Kobayashi S; Morimoto M; Ohkawa S; Koizumi W
BMC Res Notes; 2015 Oct; 8():609. PubMed ID: 26502722
[TBL] [Abstract][Full Text] [Related]
8. mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.
Meyer T; Palmer DH; Cheng AL; Hocke J; Loembé AB; Yen CJ
Liver Int; 2017 Jul; 37(7):1047-1055. PubMed ID: 28066978
[TBL] [Abstract][Full Text] [Related]
9. Influence of Tumor Cavitation on Assessing the Clinical Benefit of Anti-PD1 or PD-L1 Inhibitors in Advanced Lung Squamous Cell Carcinoma.
Chen Q; Wang J; Wang X; Yin Y; Wang X; Song Z; Xing B; Li Y; Zhang J; Qin J; Jiang R
Clin Lung Cancer; 2024 Jan; 25(1):29-38. PubMed ID: 38008641
[TBL] [Abstract][Full Text] [Related]
10. Response Assessment by Volumetric Iodine Uptake Measurement: Preliminary Experience in Patients with Intermediate-Advanced Hepatocellular Carcinoma Treated with Yttrium-90 Radioembolization.
Bargellini I; Crocetti L; Turini FM; Lorenzoni G; Boni G; Traino AC; Caramella D; Cioni R
Cardiovasc Intervent Radiol; 2018 Sep; 41(9):1373-1383. PubMed ID: 29654507
[TBL] [Abstract][Full Text] [Related]
11. Local Tumor Control and Patient Outcome Using Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: iRECIST as a Potential Substitute for Traditional Criteria.
Vernuccio F; Godfrey D; Meyer M; Williamson HV; Salama JK; Niedzwiecki D; Stephens SJ; Ronald J; Palta M; Marin D
AJR Am J Roentgenol; 2019 Dec; 213(6):1232-1239. PubMed ID: 31613663
[No Abstract] [Full Text] [Related]
12. Reclassification of therapeutic response of unresectable hepatocellular carcinoma to anti-angiogenic therapy and immunotherapy using alpha RECIST.
Xu Y; Yang Y; Ouyang J; Zhou Y; Li L; Ye F; Yang H; Huang Z; Zhou A; Zhang W; Zhou J; Zhao X; Zhao H
Eur Radiol; 2024 Apr; 34(4):2244-2255. PubMed ID: 37740779
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy.
Zheng B; Shin JH; Li H; Chen Y; Guo Y; Wang M
Korean J Radiol; 2021 Mar; 22(3):366-375. PubMed ID: 33289356
[TBL] [Abstract][Full Text] [Related]
14. The true role of mRECIST guideline: does it really estimate viable tumor or merely improve accuracy in hepatocellular carcinoma response evaluation?
Liu Q; Li A; Sun S; Luo R; Chen F
J BUON; 2014; 19(2):398-405. PubMed ID: 24965398
[TBL] [Abstract][Full Text] [Related]
15. Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis.
Mulkey F; Theoret MR; Keegan P; Pazdur R; Sridhara R
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32107275
[TBL] [Abstract][Full Text] [Related]
16. Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non-Small Cell Lung Cancer.
Beer L; Hochmair M; Haug AR; Schwabel B; Kifjak D; Wadsak W; Fuereder T; Fabikan H; Fazekas A; Schwab S; Mayerhoefer ME; Herold C; Prosch H
Clin Nucl Med; 2019 Jul; 44(7):535-543. PubMed ID: 31021918
[TBL] [Abstract][Full Text] [Related]
17. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.
Gavanier M; Ayav A; Sellal C; Orry X; Claudon M; Bronowicki JP; Laurent V
Eur J Radiol; 2016 Jan; 85(1):103-112. PubMed ID: 26724654
[TBL] [Abstract][Full Text] [Related]
18. Comparison of α-Fetoprotein Criteria and Modified Response Evaluation Criteria in Solid Tumors for the Prediction of Overall Survival of Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization.
Zhang YQ; Jiang LJ; Wen J; Liu DM; Huang GH; Wang Y; Fan WZ; Li JP
J Vasc Interv Radiol; 2018 Dec; 29(12):1654-1661. PubMed ID: 30396842
[TBL] [Abstract][Full Text] [Related]
19. Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study.
Kudo M; Finn RS; Qin S; Han KH; Ikeda K; Cheng AL; Vogel A; Tovoli F; Ueshima K; Aikata H; López CL; Pracht M; Meng Z; Daniele B; Park JW; Palmer D; Tamai T; Saito K; Dutcus CE; Lencioni R
J Hepatol; 2023 Jan; 78(1):133-141. PubMed ID: 36341767
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
Kawaoka T; Aikata H; Murakami E; Nakahara T; Naeshiro N; Tanaka M; Honda Y; Miyaki D; Nagaoki Y; Takaki S; Hiramatsu A; Waki K; Takahashi S; Chayama K
Oncology; 2012; 83(4):192-200. PubMed ID: 22890083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
